RxDoctor Payments DataLook up a doctor →

Michelle Price

Acute Care · Birmingham, ALNPI 1992057111

Payments from drug & device makers

$12,596in general payments, 2019–2025

Across 604 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • Grifols USA, LLC$842
  • Takeda Pharmaceuticals U.S.A., Inc.$808
  • Boehringer Ingelheim$784
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$12,48199%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,596 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$17,027
Medicare patients
135
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$39,508
Breo ElliptaFluticasone/Vilanterol62$29,577
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$29,410
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$12,179
EliquisApixaban13$11,785
Arnuity ElliptaFluticasone Furoate39$10,751
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,310
SymbicortBudesonide/Formoterol Fumarate13$4,807
Albuterol Sulfate HfaAlbuterol Sulfate103$2,871
Roflumilast12$1,439
Levalbuterol Tartrate HfaLevalbuterol Tartrate19$1,071
Ventolin HfaAlbuterol Sulfate14$762
Azithromycin21$725
Fluticasone Propionate22$630
Montelukast Sodium37$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta, Anoro Ellipta$2,100$79,047162 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,661$44,31568 claims
Boehringer IngelheimStiolto Respimat$784$12,17916 claims
PfizerEliquis$41$11,78513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.

Other acute care in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →